Alzheimer's disease (AD) is a public health priority for the 21 st century. Risk reduction 2 currently revolves around lifestyle changes with much research trying to elucidate the 3 biological underpinnings. Using self-report of parental history of Alzheimer's dementia for 4 case ascertainment in a genome-wide association study of over 300,000 participants from UK 5 Biobank (32,222 maternal cases, 16,613 paternal cases) and meta-analysing with published 6 consortium data (n=74,046 with 25,580 cases across the discovery and replication analyses), 7 six new AD-associated loci (P<5x10 -8 ) are identified. Three contain genes relevant for AD 8 and neurodegeneration: ADAM10, ADAMTS4, and ACE. Suggestive loci include drug targets 9 such as VKORC1 (warfarin dose) and BZRAP1 (benzodiazepine receptor). We report 3 8 3 9
1 0 evidence that association of SNPs and AD at the PVR gene is potentially mediated by both 1 1 gene expression and DNA methylation in the prefrontal cortex. Our discovered loci may help 1 2 to elucidate the biological mechanisms underlying AD and, given that many are existing drug 1 3 targets for other diseases and disorders, warrant further exploration for potential precision 1 4 medicine applications.
1 5
Family history of Alzheimer's disease was ascertained via self-report. Participants were 1 0 0 asked "Has/did your father ever suffer from Alzheimer's disease/dementia?" and "Has/did 1 0 1 your mother ever suffer from Alzheimer's disease/dementia?" Self-report data from the initial 1 0 2 assessment visit (2006) (2007) (2008) (2009) (2010) , the first repeat assessment visit (2012) (2013) , and the imaging 1 0 3 visit (2014+) were aggregated with exclusions made for participants whose parents were: 1 0 4 aged under 60 years; dead before reaching age 60 years; without age information. After disease prevalence due to sex differences in longevity -AD prevalence was double in 1 0 8 mothers compared to fathers -GWA studies were performed separately for maternal and 1 0 9 paternal AD. The GWA studies were conducted using BGENIE. 8 The outcome variable was the residuals 1 1 3 from a linear regression model of maternal or paternal AD on age of parent at death or at time 1 1 4 of the offspring's self-report, assessment centre, genotype batch, array, and 40 genetic 1 1 5 principal components. The predictor variable was the autosomal SNP and an additive model 1 1 6 was considered. The GWAS linear regression coefficients were converted to odds ratios using observed 1 1 9 sample prevalences of 0.096 and 0.055 for maternal and paternal AD, respectively, 11 before 1 2 0 the log-odds were multiplied by two, in this way the effect size are reported on the same scale 1 2 1 as a traditional case-control design. 6 Standard errors for the log-odds were then calculated 1 2 2 based on the adjusted OR and the P-value from the initial GWAS (Supplementary Note 1) .
The ORs and standard errors were then carried forward to a weighted meta-analysis in 1 2 4 1 3 8 of 0.05/18,251 = 2.7x10 -6 was used to identify significant genes. To test for pleiotropic associations between AD and gene expression/DNA methylation in the 1 4 2 brain, summary-data based Mendelian Randomization (SMR) was performed. 18 > 13). 19 The reference genotypes were based on the Health and Retirement Study, imputed to 1 4 8 2 8 2 was a genome-wide significant SNP in a trans-ethnic study of AD. 34 BZRAP1 is involved in basis for what many considered to be an observation based on reverse causality. An integrative analysis of eQTL and methQTL with the GWAS summary data identified one 2 8 8 previously identified AD gene, PVR, as having its gene expression and methylation levels 2 8 9 associated with AD. The most parsimonious explanation of these results is the existence of 2 9 0 multiple causal variants, some affecting AD and others affecting expression or methylation. PVR is a poliovirus receptor in the APOE/TOMM40 cluster on chromosome 19 that has been 2 9 2 hypothesised to influence the risk of AD through susceptibility to viral infections. 51 A 2 9 3 previous SMR analysis of AD and LDL-cholesterol identified evidence of 16 pleiotropic 2 9 4
SNPs, 12 of which were located in the APOE region. 52 2 9 5 2 9 6
The main strength of the study is the proxy phenotype approach, which resulted in over 48,000 proxy-cases, which has roughly equivalent power to a study of 12,000 observed 2 9 8 cases. 6 However, the question used to determine parental AD status may have resulted in 2 9 9 some responders being unable to discriminate Alzheimer's disease and dementia from other 3 0 0 dementia sub-types, which have different presentations and genetic architectures. 53, 54 dementia status is partly dependent on longevity, with age being the biggest risk factor for 3 0 3 AD. We partially controlled for this by excluding participants whose parents were younger 3 0 4 than or died prior to reaching the age of 60 years when AD incidence is extremely low. The to detect true effects. This, along with a possible winner's curse effect for the IGAP study, 3 0 7 might explain the reduction in the meta-analytic odds ratios compared to those previously The therapeutics field for disease modification in AD is now benefitting from more accurate, for precision medicine is the ability to identify sub-populations of a clinical condition who 3 1 4 share a common, relevant and targetable disease mechanism. 56 Stratification of samples for where associated disease processes are known to be relevant, and for which pharmacological We identified three new AD-associated loci that have known and putative biological 3 2 3 processes associated with Alzheimer's disease. Suggestive (P<1x10 -5 ) associations included 3 2 4 loci linked to common diseases and health measures that are comorbid with, or commonly 3 2 5 used to predict risk of AD. These findings help to elucidate the biological mechanisms 3 2 6 underlying AD and, given that some (VKORC1, ACE, BZRAP1) are existing drug targets for 3 2 7 other diseases and disorders, warrant further exploration for potential precision medicine and 3 2 8 clinical trial applications. Supplementary information is available at MP's website. Foundation. Alison Goate is on the scientific advisory board for Denali Therapeutics and 3 4 8 has served as a consultant for AbbVie and Cognition Therapeutics. The funders had no role in study design, data collection and analysis, decision to publish, or 3 5 1 preparation of the manuscript. There are no financial conflicts of interest for any of the authors. (Excel file)   Table S1 . Independent genome-wide significant AD loci from the meta-analysis of UK Biobank and IGAP summary statistics Table S2 . Summary output from the GWAS meta-analysis of maternal and paternal AD in UK Biobank with IGAP Table S3 . Lookup of genome-wide significant loci identified in Lambert et al. Table S4 . Independent genome-wide significant (P<5x10-8) and suggestive AD loci (P<1x10-5) from the meta-analysis of UK Biobank and IGAP summary statistics Table S5 . GWAS catalog output for SNPs at loci with a lead SNP at P<1x10-5 Table S6 . MAGMA gene-based associations for the UK Biobank and IGAP meta-analysis summary results Table S7 . Gene Ontology enrichment analysis for the genome-wide significant genes Table S8 . SMR analysis of AD GWAS summary output and brain expression QTL summary output (adjusted for diagnosis, institution, sex, age of death, post-mortem interval, RNA integrity number (RIN), RIN^2, and clustered library batch) Table S9 . SMR analysis of AD GWAS summary output and brain expression QTL summary output (adjustment for diagnosis, institution, sex, age of death, post-mortem interval, RNA integrity number (RIN), RIN^2, clustered library batch, and 20 surrogate variables) Table S10 . SMR analysis of AD GWAS summary output and brain methylation QTL summary output (adjusted for 5 genetic MDS components and 11 methylation PCs)
